Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Day Range47.350 - 48.760 | 52 Wk Range42.420 - 66.000 | Open / Close47.350 / - | Float / Outstanding82.342M / 94.705M |
Vol / Avg.204.554K / 619.387K | Mkt Cap4.580B | P/E- | 50d Avg. Price51.010 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float82.342M | EPS-3.320 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-28 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.810 | -0.570 | 0.2400 | ||||
REV | 66.000M | 71.870M | 5.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Goldman Sachs on Monday, August 22, 2022. The analyst firm set a price target for 49.00 expecting ITCI to rise to within 12 months (a possible 1.32% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $48.36 last updated Today at January 31, 2023 at 5:54 PM UTC.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q4 earnings are confirmed for Tuesday, February 28, 2023.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.